New primary monoclonal antibodies · 25. November 2022
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
Ion channel therapeutic monoclonal antibodies · 22. October 2022
SYnAbs' unique approach generating ultra-specific therapeutic monoclonals to ion channels and effectively treat channelopathies thanks to a unique antibody platform
New primary monoclonal antibodies · 03. October 2022
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
GPCR therapeutic monoclonal antibodies · 20. September 2022
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications
GPCR therapeutic monoclonal antibodies · 13. August 2022
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins
Ion channel therapeutic monoclonal antibodies · 12. July 2022
SYnAbs has developed R&D and therapeutic monoclonal antibodies against transporters and ion channel such as glutamate EAAT transmembrane targets thanks to peptide and syngeneic cell immunization strategies
Anti-small molecule hapten antibodies · 09. June 2022
SYnAbs develops therapeutic IgG antibodies highly specific to carbohydrates by combining unique technologies and expertise to break immune tolerance in rat-LOU and transgenic animal species
GPCR therapeutic monoclonal antibodies · 30. April 2022
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
GPCR therapeutic monoclonal antibodies · 05. April 2022
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise
GPCR therapeutic monoclonal antibodies · 19. March 2022
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
